Crinetics partners to commercialize its paltusotine in Japan

Crinetics Pharmaceuticals, a USA-based clinical-stage developer of novel therapeutics for rare endocrine diseases and endocrine-related tumors, has teamed up with Sanwa Kagaku Kenkyusho to exclusively develop and commercialize in Japan.

Paltusotine is Crinetics’ investigational, orally available non-peptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome.

There are approximately 10,000 acromegaly patients and 11,000 NETs patients in Japan and, as in the USA, somatostatin analogues are the first-line medical therapy for individuals for whom surgery is either not prescribed or is not curative.